| Ø     
  There are clear,
  though non-definitive indications of the therapeutic benefits of marijuana in
  the following conditions: analgesic for chronic pain, antispasm for multiple
  sclerosis, anticonvulsive for epilepsy, antiemetic for chemotherapy and
  appetite stimulant for cachexia.  Ø      There are less clear indications
  regarding the effect of marijuana on glaucoma and other medical conditions.
    
   Ø      Marijuana has not been established
  as a drug through rigorous, controlled studies.  Ø      The quality and effectiveness of
  marijuana, primarily smoked marijuana, have not been determined in clinical
  studies.     Ø      There have been some studies of
  synthetic compounds, but the knowledge base is still too small to determine
  effectiveness and safety.  Ø      Generally, the effects of smoked
  marijuana are more specific and occur faster than the effects of synthetic
  compounds.  Ø      The absence of certain cannabinoids
  in synthetic compounds can lead to harmful side effects, such as panic
  attacks and cannabinoid psychoses.  Ø      Smoked marijuana is potentially
  harmful to the respiratory system.  Ø      People who smoke marijuana for
  therapeutic purposes self-regulate their use depending on their physical
  condition and do not really seek the psychoactive effect   Ø      People who smoke marijuana for
  therapeutic purposes prefer to have a choice as to methods of use.     Ø      Measures should be taken to
  support and encourage the development of alternative practices, such as the
  establishment of compassion clubs.  Ø      The practices of these
  organizations are in line with the therapeutic indications arising from
  clinical studies and meet the strict rules on quality and safety        Ø      The studies that have already been
  approved by Health Canada must be conducted as quickly as possible.  Ø      The qualities of the marijuana
  used in those studies must meet the standards of current practice in
  compassion clubs, not NIDA standards.  Ø      The studies should focus on
  applications and the specific doses for various medical conditions.  Ø      Health Canada should, at the
  earliest possible opportunity, undertake a clinical study in cooperation with
  Canadian compassion clubs.  |